Development strategy of tumor diagnostic agent by system upregulated functional biomolecule based on expression analysis of tumor associated transporter
本研究では、薬剤評価に用いるヒト培養細胞の遺伝子発現レベルをデータベース化し、癌細胞に高発現している機能性分子を予め探索するとともに、ヒト腫瘍培養細胞で高発現を確認した機能性分子安定発現系を画像診断薬のスクリーニングに利用して、ポストFDG 製剤の有力候補である標識アミノ酸製剤のアミノ酸トランスポーター及び薬物トランスポーターに対する親和性を詳細に検討し、アミノ酸トランスポーター遺伝子発現と腫瘍集積性との相関からその設計戦略の妥当性を評価した。
In this study, while searching this research for the functional biomolecule used by the database for the gene expression level in the human cultured cells for evaluation of imaging probes, as well as human tumor culturing cells in a stable functional molecule was confirmed with high expression by using the expression system for the screening of imaging agents, the labeled amino acid derivatives are especially taken up also in a post-FDG candidate probe, and the accumulation mechanism of the labeled amino acids which shows high affinity to the amino acid transporters to which high revelation is specifically accepted by a tumor was examined in detail, and the validity of the design strategy was evaluated from correlation with amino acid transporter gene expression and tumor accumulation of the imaging agents.
癌関連トランスポーター発現解析に基づく機能性分子発現系による腫瘍診断薬の開発戦略
.png)
ME-PR-KAWAI-K-kaken 2017-5p.pdf
(257.89KB)
